ReviewFrontiers in cardiovascular medicine2021
Bacterial-Induced Blood Pressure Reduction: Mechanisms for the Treatment of Hypertension
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- Trial
- Distinct SCFA profiles drive contrasting impacts of whole versus refined grains on metabolic health and body composition beyond inflammation in older adults: a secondary analysis of a randomized controlled trial.Nutrition & metabolism · 2026Article
- Microbiota in Gut-Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease.Comprehensive physiology · 2025Review
- The Detrimental Impact of Ultra-Processed Foods on the Human Gut Microbiome and Gut Barrier.Nutrients · 2025Review
- Identifying potential drugs for treating Cardiovascular-kidney metabolic syndrome via reverse network pharmacology.Frontiers in pharmacology · 2025Article
- The living medicine inside us:Gut microbes reports · 2025Article
- Exploring the Interplay of Gut Microbiota and Systemic Inflammation in Pediatric Obstructive Sleep Apnea Syndrome and Its Impact on Blood Pressure Status: A Cross-Sectional Study.International journal of molecular sciences · 2024Article
- OraliScience · 2024Article
- Review
- Impact of fundamental components of the Mediterranean diet on the microbiota composition in blood pressure regulation.Journal of translational medicine · 2024Review
- Review
- Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives.Applied microbiology and biotechnology · 2024Review
- Microbial influence on blood pressure: unraveling the complex relationship for health insights.Microbiome research reports · 2024Article
- Probiotics as potential treatments to reduce myocardial remodelling and heart failure via the gut-heart axis: State-of-the-art review.Molecular and cellular biochemistry · 2023Review
- Food Peptides, Gut Microbiota Modulation, and Antihypertensive Effects.Molecules (Basel, Switzerland) · 2022Review
- Regulatory effect of gut microbes on blood pressure.Animal models and experimental medicine · 2022Review
- The PPARα Regulation of the Gut Physiology in Regard to Interaction with Microbiota, Intestinal Immunity, Metabolism, and Permeability.International journal of molecular sciences · 2022Review
- Intestinal microbiota: A promising therapeutic target for hypertension.Frontiers in cardiovascular medicine · 2022Review
- Chemokine-like Receptor 1 in Brain of Spontaneously Hypertensive Rats Mediates Systemic Hypertension.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a major risk factor for the development of cardiovascular disease. As more research into the gut microbiome emerges, we are finding increasing evidence to support that these microbes may have significant positive and negative effects on blood pressure and associated disorders. The bacterial-derived metabolites that are produced in the gut are capable of widespread effects to several tissue types and organs in the body. It is clear that the extensive metabolic function that is lost with gut dysbiosis is unlikely to be replenished with a single metabolite or bacterial strain. Instead, combinations of bacteria and concomitant therapies will provide a more well-rounded solution to manage hypertension. The bioactive molecules that are recognized in this review will inform on ideal characteristics of candidate bacteria and provide direction for future research on the gut microbiome in hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.